Today I am launching the Free Radicals podcast with @EricDai_BioE . Every Tuesday, we’ll be releasing long form conversations with the visionaries giving humanity control over biology and working to dramatically extend human lifespan. We’re thrilled to host @celinehalioua, Founder CEO @loyalfordogs, for our inaugural episode. Celine is building the world’s first lifespan extension drugs for dogs. Follow me, @EricDai_BioE and @FreeRadicalsBio for new episodes every Tuesday. 00:00:00 - Intro 00:01:51 - Celine’s background 00:05:00 - Dropping out of academia 00:07:50 - Finding ways to increase free will 00:09:36 - How to align financial incentives with longevity 00:14:52 - Longevity drugs should be boring 00:21:24 - Celine’s leadership style 00:24:08 - Advice on fundraising and constructing feedback loops 00:26:52 - Loyal’s fundraising history 00:27:57 - Building for Zero Billion Dollar Markets 00:29:11 - How to succeed in biotech 00:30:21 - How to find blockbuster opportunities 00:33:25 - How to create a gold rush in longevity 00:35:25 - The problem with the aging field 00:39:32 - How to identify signal from noise 00:41:54 - AI applications to biology 00:45:15 - Importance of naiveté 00:47:24 - FREE RADICALS

Free Radicals is back! Today’s guest is @ElliotHershberg, partner at @AmplifyPartners and author of the popular blog Century of Biology. We talk about GLP-1s as a breakthrough moment for biotech, why drug development is starting to behave like software, and how falling discovery costs could finally free biotech startups from selling themselves to pharma. Other topics include Elliot’s "massive markets, medium prices" thesis, the rise of consumer and "n-of-one" medicine, and Sid Sijbrandij @sytses going founder mode on his own cancer. Thank you to @SynBioBeta for hosting us at their conference, where we recorded this episode, and several others we’ll be releasing soon! Follow me, @FreeRadicalsBio & @EricDai_BioE for weekly episodes with leaders in biotech and longevity. 0:00 Intro 2:12 What era of biotech are we in? 3:58 GLP-1s: the once-in-a-generation breakthrough 7:04 Inside Lilly's trillion-dollar valuation 9:09 The Gillette Era of GLP1s 9:54 The Bryan Johnson Era of Biotech: Biohacking goes mainstream 12:55 The $1T question on Consumer Biotech 14:33 Patent cliffs, fast followers, and building for "me-last" therapies 18:20 Disintermediating pharma: HIMS, Loyal, and the standalone biotech 19:41 Why do biotechs sell to pharma in the first place? 23:03 Longevity: a science problem or an ecosystem-alignment problem? 27:14 Why GLP-1s came from pharma 29:52 Why Elliot is Bullish on Standalone Biotechs 33:03 Is Drug Development Becoming more like Software? Not if upside is capped at <$10B 41:30 The geroscience hypothesis and longevity as massive markets, medium prices 45:36 Treating age related diseases or aging as an indication 47:55 How do you value curing aging?

"Longevity is the most important problem of humanity we have to solve soon with the help of AI; billions of lives are at stake." That's how @DeryaTR_ framed his upcoming talk at @VitalistBay. The AI x Bio track lineup ↓

New episodes of @FreeRadicalsBio will be on pause until May 26th because we’re taking our show on the road! This week we’re at @SynBioBeta. Next week @VitalistBay. We’ll be recording conversations with some amazing leaders in AI and Bio at these conferences! We’ll be back to our regular weekly episodes soon. And on a personal note this is the first time I’ve ever been at an event as a member of the press

So excited for the future

"All great snake oil... all great lies are built on a seed of truth. The reason there's so much excitement around longevity is that we are able to modify aging biology in animals... and there are drugs in clinical trials... but consumers are not patient." In today's episode of the @FreeRadicalsBio podcast, we dive into the history of the geroscience field with Dr. @JamesPeyer, founder & CEO @CambrianBio. We discuss what makes geroscience's approach drug development so unique, how to unlock the flywheel of innovation that will get us longevity escape velocity, and Amplifier Therapeutics' "zone 2 in a pill"... which might prove to be the first ever true longevity drug. Follow me and @EricDai_BioE to stay up to date on the latest news in longevity biotech!

1/ How long do you want to live? For most of human history, aging was inevitable. It's now solvable. Apply for LBF8 cohort program: longbiofellowship dot org /THREAD🧵

Health and wellness will be the biggest market in the world. It’s inevitable.

“You’re born, you grow up, you have a career, and then you get older and then you die. And that's just like the acceptable plan. Even if the plan is horrible… as long as we're going to plan, everybody goes along with it.” @realNathanCheng is one of the most prolific activists in the longevity field. He argues that aging, decline and death are not really a great plan, even if it's the way things work today. He has dedicated his life and career to finding us a new plan. Follow me and @EricDai_BioE to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:35 Why did Nathan dedicate his life to defeating aging & death? (And the absurdity of asking that question) 8:59 Why has Daniel been on the fence, despite being longevity-pilled 14:09 The agency and bravery of founders to tackle the hardest problems (like aging) 18:46 Many ways to contribute to longevity besides entrepreneurship 19:41 Is longevity underinvested into? 24:48 What does it mean to treat aging itself as the issue (vs other diseases) 32:23 Do we need more scientific arguments, or philosophical arguments? 39:50 Nathan’s experience longevity-pilling influential people 47:03 Billionaire paradox 53:18 The challenge in going from viewing aging as inevitable to malleable 57:29 What needs to change about our culture to save us from aging & death 1:16:55 Should we be intolerant of pro-death & pro-aging views? 1:22:59 Join us at Vitalist Bay!

What will future AI enable in bio? That depends on the training datasets we choose to generate now. @MartinBJensen: “How do you treat this disease? [...] is it one disease or five different things with different drivers? [This] is way underspecified. Solving those kinds of problems [needs] different kinds of data input. In vivo perturbation at scale [...], I think is one thing you can do." - Free Radicals podcast with @EricDai_BioE and @teleodaniel